The stock price of Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) has surged by 2.81 when compared to previous closing price of 43.82, but the company has seen a 3.99% gain in its stock price over the last five trading sessions. CNBC Television reported 2024-04-03 that Michelle Ross, StemPoint Capital CIO, joins CNBC’s Halftime Report’ to discuss her latest biotech pick.
Is It Worth Investing in Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) Right Now?
The 36-month beta value for CRNX is at 0.63. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for CRNX is 72.12M, and currently, shorts hold a 7.24% of that float. The average trading volume for CRNX on May 02, 2024 was 798.14K shares.
CRNX’s Market Performance
CRNX’s stock has seen a 3.99% increase for the week, with a -2.07% drop in the past month and a 23.49% gain in the past quarter. The volatility ratio for the week is 4.89%, and the volatility levels for the past 30 days are at 5.05% for Crinetics Pharmaceuticals Inc The simple moving average for the past 20 days is 0.78% for CRNX’s stock, with a 40.13% simple moving average for the past 200 days.
Analysts’ Opinion of CRNX
Many brokerage firms have already submitted their reports for CRNX stocks, with Citigroup repeating the rating for CRNX by listing it as a “Buy.” The predicted price for CRNX in the upcoming period, according to Citigroup is $68 based on the research report published on March 06, 2024 of the current year 2024.
Morgan Stanley, on the other hand, stated in their research note that they expect to see CRNX reach a price target of $50. The rating they have provided for CRNX stocks is “Overweight” according to the report published on January 16th, 2024.
Jefferies gave a rating of “Hold” to CRNX, setting the target price at $35 in the report published on December 21st of the previous year.
CRNX Trading at 4.62% from the 50-Day Moving Average
After a stumble in the market that brought CRNX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -9.14% of loss for the given period.
Volatility was left at 5.05%, however, over the last 30 days, the volatility rate increased by 4.89%, as shares sank -5.40% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +20.39% upper at present.
During the last 5 trading sessions, CRNX rose by +3.99%, which changed the moving average for the period of 200-days by +125.70% in comparison to the 20-day moving average, which settled at $44.57. In addition, Crinetics Pharmaceuticals Inc saw 26.62% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CRNX starting from Pizzuti Dana, who sale 14,375 shares at the price of $44.47 back on Apr 15 ’24. After this action, Pizzuti Dana now owns 27,786 shares of Crinetics Pharmaceuticals Inc, valued at $639,256 using the latest closing price.
Struthers Richard Scott, the President & CEO of Crinetics Pharmaceuticals Inc, sale 40,951 shares at $49.17 during a trade that took place back on Apr 04 ’24, which means that Struthers Richard Scott is holding 237,835 shares at $2,013,561 based on the most recent closing price.
Stock Fundamentals for CRNX
Current profitability levels for the company are sitting at:
- -55.47 for the present operating margin
- 0.67 for the gross margin
The net margin for Crinetics Pharmaceuticals Inc stands at -52.96. The total capital return value is set at -0.38. Equity return is now at value -50.16, with -43.45 for asset returns.
Based on Crinetics Pharmaceuticals Inc (CRNX), the company’s capital structure generated 0.09 points at debt to capital in total, while cash flow to debt ratio is standing at -3.22. The debt to equity ratio resting at 0.1. The interest coverage ratio of the stock is 112.26.
Currently, EBITDA for the company is -221.51 million with net debt to EBITDA at 0.01. When we switch over and look at the enterprise to sales, we see a ratio of 874.05. The receivables turnover for the company is 0.43for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.07.
Conclusion
In conclusion, Crinetics Pharmaceuticals Inc (CRNX) has had a better performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
